Boehringer Ingelheim has entered a multi-year agreement with Brigham and Women's Hospital, a teaching affiliate of Harvard Medical School, under which, Brigham will conduct a long-term study to assess comparative effectiveness and safety, as well as prescribing patterns, of oral anticoagulants, including Pradaxa, for the reduction of stroke risk in U.S. patients with non-valvular atrial fibrillation (NVAF).
The long-term study aims to better understand the safety and effectiveness of warfarin and newer oral anticoagulants. Brigham and Women's Hospital will analyze claims data from UnitedHealth Group's research database, which is managed by one of the largest health care companies in the U.S., serving more than 80 million people worldwide.
"Our support of the study program being conducted by Brigham and Women's Hospital is a sign of our shared commitment to help improve healthcare delivery and outcomes for the estimated five million patients with non-valvular atrial fibrillation in the U.S. who are at increased risk for stroke," said Sabine Luik, M.D., senior vice president, medicine & regulatory affairs, U.S. regional medical director, Boehringer Ingelheim Pharmaceuticals, Inc. "As a science-based company, Boehringer considers patient safety and education as top priorities and we remain dedicated to research and education which fosters greater public health."
Boehringer, Brigham and Women's Hospital in CE Study Agreement
Published August 15, 2013
blog comments powered by Disqus